Tarsus Pharmaceuticals (NASDAQ:TARS) Research Coverage Started at Barclays

Barclays began coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) in a report released on Monday morning, The Fly reports. The brokerage issued an overweight rating and a $40.00 price objective on the stock.

TARS has been the subject of several other research reports. HC Wainwright restated a buy rating and set a $40.00 price target on shares of Tarsus Pharmaceuticals in a research note on Tuesday, May 3rd. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $55.00 to $66.00 in a research note on Monday, May 2nd.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $15.30 on Monday. Tarsus Pharmaceuticals has a twelve month low of $10.80 and a twelve month high of $31.00. The company has a current ratio of 14.18, a quick ratio of 14.18 and a debt-to-equity ratio of 0.13. The business has a 50 day simple moving average of $14.40 and a 200-day simple moving average of $16.10. The company has a market capitalization of $317.12 million, a P/E ratio of -7.05 and a beta of 1.02.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.11). Tarsus Pharmaceuticals had a negative return on equity of 25.85% and a negative net margin of 184.14%. The company had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $5.50 million. As a group, equities analysts anticipate that Tarsus Pharmaceuticals will post -3.37 EPS for the current year.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, major shareholder Vivo Capital Ix, Llc sold 19,738 shares of the stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $12.67, for a total value of $250,080.46. Following the completion of the transaction, the insider now owns 2,474,375 shares in the company, valued at $31,350,331.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Tarsus Pharmaceuticals news, Director Michael Ackermann acquired 100,000 shares of the business’s stock in a transaction on Thursday, May 5th. The stock was purchased at an average price of $13.50 per share, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 100,000 shares of the company’s stock, valued at approximately $1,350,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Vivo Capital Ix, Llc sold 19,738 shares of the firm’s stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $12.67, for a total value of $250,080.46. Following the completion of the transaction, the insider now owns 2,474,375 shares of the company’s stock, valued at approximately $31,350,331.25. The disclosure for this sale can be found here. 33.08% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its position in shares of Tarsus Pharmaceuticals by 3.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after buying an additional 1,402 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Tarsus Pharmaceuticals by 221.0% in the first quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company’s stock valued at $485,000 after buying an additional 19,865 shares in the last quarter. Invesco Ltd. increased its position in shares of Tarsus Pharmaceuticals by 17.1% in the first quarter. Invesco Ltd. now owns 27,982 shares of the company’s stock valued at $471,000 after buying an additional 4,078 shares in the last quarter. UBS Group AG increased its position in shares of Tarsus Pharmaceuticals by 37.0% in the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after buying an additional 1,142 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Tarsus Pharmaceuticals by 19.0% in the second quarter. SG Americas Securities LLC now owns 50,512 shares of the company’s stock valued at $737,000 after buying an additional 8,073 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

See Also

The Fly logo

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.